Antithrombin III Arg79Cys — A High-Penetrance Clotting Barrier Breach
Antithrombin III — encoded by SERPINC1 — is the body's primary brake on the coagulation
cascade. It neutralizes thrombin and activated Factor Xa, directly blocking the two central
enzymes that form fibrin clot. When antithrombin works at full capacity, a runaway clotting
reaction cannot occur. The Arg79Cys variant destroys part of that brake. Carriers produce
antithrombin protein with a crippled heparin-binding domain, and the crippled protein cannot
do its job — the coagulation system runs hotter and clots more readily. The result is one of
the strongest known inherited thrombophilias, with a risk of venous thromboembolism (VTE)
estimated at 14-fold above the general population | Croles et al., 2018 Bayesian
meta-analysis of 19 studies, Semin Thromb Hemost.
The Mechanism
The SERPINC1 gene is on the minus strand of chromosome 1 (position 173,914,726 on GRCh38).
The Arg79Cys variant arises from a CpG dinucleotide hotspot | CpG sites are hypermutable
because cytosine methylation spontaneously deaminates to thymine; recurrent independent
mutations at the same codon are common in antithrombin deficiency
in exon 2 of SERPINC1, where a G-to-A change on the plus strand converts arginine at position
79 to cysteine in the mature protein. Arginine-79 is located in the [heparin-binding domain |
The N-terminal region of antithrombin that physically contacts heparan sulfate proteoglycans
on endothelial cells, dramatically accelerating the inhibitory rate constant] near the
N-terminus of the protein. Arginine's positively charged guanidinium group makes electrostatic
contact with negatively charged heparin; cysteine, with its uncharged thiol, cannot replicate
this interaction. The result is a [Type II heparin-binding site (HBS) deficiency | The WHO
classifies antithrombin deficiency into Type I (quantitative: low antigen and activity) and
Type II (qualitative: normal antigen, reduced activity). Arg79Cys is a Type II HBS variant]:
the protein is present in normal amounts but cannot bind heparin at full affinity, impairing
the 1,000-fold rate acceleration that heparin normally provides to the inhibitory reaction.
Heterozygous carriers have functional antithrombin activity typically around 50-75% of normal
— enough to prevent spontaneous thrombosis in many circumstances, but not enough to withstand
strong provoking stimuli: surgery, pregnancy, immobility, estrogen exposure, or concurrent
thrombophilic variants.
The Evidence
The evidence base for antithrombin deficiency and VTE is among the most robust in inherited
thrombophilia. A Bayesian meta-analysis of 19 studies by Croles and colleagues | 2018,
Seminars in Thrombosis and Hemostasis calculated
a pooled OR of 14.0 (95% credible interval 5.5-29.0) for first VTE in antithrombin-deficient
individuals. Annual VTE incidence was 1.2% in deficient individuals versus 0.07% in the general
population — a 17-fold difference in absolute rates. After a first VTE, annual recurrence
without anticoagulation reached 8.8% versus 4.3% in non-deficient patients.
A separate meta-analysis by Di Minno et al. | 13 studies, 3,452 VTE cases; Thrombosis
Research 2015 confirmed an OR of 16.26 (95% CI
9.90-26.70), making antithrombin deficiency substantially stronger than either Factor V Leiden
(OR ~5-7) or prothrombin G20210A (OR ~3-5).
A nuance relevant to rs121909547 specifically: because Arg79Cys is a Type II HBS mutation,
it may carry somewhat lower risk than Type I (quantitative) deficiency. A retrospective cohort
of 540 SERPINC1 mutation carriers by Alhenc-Gelas et al. | Thrombosis and Haemostasis
2017 found that Type II HBS mutations had an
adjusted relative risk of 0.28 compared to Type I mutations — still representing a substantial
absolute VTE risk, but a meaningful gradient worth knowing for clinical counseling. Even at the
lower end of the antithrombin deficiency risk spectrum, the absolute VTE risk substantially
exceeds that of Factor V Leiden or prothrombin G20210A.
Practical Actions
The clinical management of antithrombin deficiency centers on three domains. First,
thromboprophylaxis during high-risk periods: surgery, hospitalization, prolonged immobility,
and pregnancy each require active management. Second, contraception and hormonal therapy:
estrogen-containing hormonal contraceptives are generally avoided because estrogen is itself
prothrombotic and the combination multiplies risk dramatically. Third, anticoagulation
after any VTE event: given the high recurrence rate (8.8%/year without anticoagulation),
extended or indefinite anticoagulation is typically recommended after a first unprovoked VTE.
Antithrombin concentrate (plasma-derived or recombinant) is available for acute thrombosis or
high-risk situations (peri-surgical, peri-partum) in deficient individuals when standard
anticoagulation is insufficient. This is a specialist-level intervention, but carriers should
know it exists.
Hematology referral for formal thrombophilia evaluation is recommended for all carriers.
Interactions
The most clinically important interactions are additive with other prothrombotic states. A
carrier of rs121909547 who also carries Factor V Leiden (rs6025) or prothrombin G20210A
(rs1799963) has independent defects in both coagulation inhibition and coagulation factor
overproduction — a multiplicative risk combination. Acquired prothrombotic conditions
(antiphospholipid syndrome, myeloproliferative neoplasms, cancer, nephrotic syndrome) also
compound with antithrombin deficiency in a clinically significant way.
During pregnancy, antithrombin levels physiologically decline by 20-30% in the third trimester,
which means a carrier starts closer to the critical threshold for thrombosis and falls below
it more easily. Antithrombin concentrate is sometimes used peripartum in this setting.
Alla genotyper
Normal antithrombin function — no SERPINC1 Arg79Cys thrombophilia
You carry two copies of the reference G allele at rs121909547. Your SERPINC1 gene produces antithrombin III with an intact heparin-binding domain, providing full anticoagulant protection. This is the common genotype found in over 99.99% of the population. You do not carry the Arg79Cys antithrombin deficiency variant.
One copy of Arg79Cys — antithrombin III deficiency with approximately 14-fold elevated VTE risk
You carry one copy of the Arg79Cys pathogenic variant in SERPINC1. This causes a qualitative antithrombin deficiency: your antithrombin protein is present but its heparin-binding capacity is reduced, leaving the coagulation cascade less well controlled. Heterozygous antithrombin deficiency is associated with a pooled odds ratio of approximately 14 for venous thromboembolism — far higher than the more common Factor V Leiden or prothrombin G20210A variants. The Arg79Cys mutation is classified Pathogenic by the ClinGen Thrombosis Expert Panel. This variant is extremely rare, present in roughly 1 in 10,000 individuals globally.
Two copies of Arg79Cys — homozygous antithrombin deficiency, extremely rare and very high thrombosis risk
You carry two copies of the Arg79Cys pathogenic variant, making you homozygous for this antithrombin deficiency mutation. This genotype is exceptionally rare — essentially absent from population databases, with fewer than a handful of documented homozygous cases in the medical literature. Homozygous antithrombin deficiency causes severe, often neonatal- onset thrombosis and typically requires continuous anticoagulation from early life. If this result is confirmed, urgent specialist evaluation is required.